Clinical Research Directory
Browse clinical research sites, groups, and studies.
Methylene Blue for the Prevention of Hypotension During Hemodialysis
Sponsor: Federal University of São Paulo
Summary
Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.
Official title: Methylene Blue for the Prevention of Hypotension During Hemodialysis: a Randomized Open Label Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2021-10-21
Completion Date
2025-12
Last Updated
2025-04-03
Healthy Volunteers
No
Conditions
Interventions
Methylene Blue
1 mg per kilogram bolus, followed by 0.1 milligram per kilogram during renal replacement therapy
Control
Usual care during renal replacement therapy
Locations (1)
Federal University of São Paulo
São Paulo, São Paulo, Brazil